by Madaline Spencer | Jul 9, 2026
Rachel Gafni, MD, Senior Research Physician at the National Institutes of Health, discusses results from the CALIBRATE clinical trial in patients with autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare form of hypoparathyroidism caused by...
by Madaline Spencer | Jul 8, 2026
Melanie Gander, mother of a son with congenital adrenal hyperplasia (CAH), and Ambassador with Neurocrine Biosciences, discusses her son’s diagnostic journey with congenital adrenal hyperplasia. CAH refers to a group of genetic conditions that affect the...
by Madaline Spencer | Jul 7, 2026
Kate Stratton, Executive Director of Lipodystrophy United, discusses mental health challenges and care gaps in patients with lipodystrophy. Lipodystrophies are rare metabolic disorders characterized by the loss of adipose tissue. This leads to...
by Madaline Spencer | Jul 6, 2026
Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses treatment with Xywav (low sodium oxybate) in patients with sleep disorders, narcolepsy and idiopathic hypersomnia. ...
by Madaline Spencer | Jul 3, 2026
The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug) for the treatment of thyroid eye disease (TED), regardless of TED’s duration or activity. TED is a chronic endocrine, autoimmune disease characterized by immune-mediated orbital...
